NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

TXG

TXG US Stock
$200
Open: $191.81 High: $195.8 Low: $178.48 Close: $180.74
Range: 2021-04-19 - 2021-04-20
Volume: 768,725
Market: Extended-hours
Powered by Finage Stock APIDelayed data
TXG
  • CEO:
  • Employees:
  • Sector:
  • Industry:
TXG News
Latest news about the TXG
  • Dow Jones Futures Fall, Bitcoin Slumps As Stock Market Rally Enters Power Trend; Square, Apple, Tesla In Focus

    The bull market is now in a Power Trend, but note key warning signs too. Bitcoin plunged from record highs. Square and other growth plays have handles. Will Tesla join them?

    View More →
  • Coronavirus Vaccine Plays Moderna, Maravai Among 5 Stocks Near Buy Points

    Coronavirus vaccine maker Moderna and vaccine suppliers Maravai and West Pharmaceutical are among five stocks in or near buy zones.

    View More →
  • 3 Hot Healthcare Stocks Cathie Wood Is Buying in April

    ARK Invest CEO Cathie Wood stated in December that "the biggest upside surprises are going to come from the genomic space." Wood's ARK Innovation ETF has scooped up shares of Beam Therapeutics (NASDAQ: BEAM) on six different days so far this month.

    View More →
  • Is TXG Stock A Buy or Sell?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 887 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of December 31st, 2020. […]

    View More →
  • Square, Shopify Lead Five 2020 Winners Setting Up For Another Run

    Etsy, 10X Genomics, Shopify, Pinterest and Square are big 2020 winners setting up near buy points as growth stocks join the market rally.

    View More →
  • How Does 10x Genomics Handle Product Development?

    Tom Gardner: I'm wondering how your product development process works, if it's changed since inception of the company or if you came to the table, given your past experiences of the prior organization you were working with your game plan for product development. Serge Saxonov: Really good question and it goes to the heart of a lot of how we do things at 10x.

    View More →
  • How 10x Genomics Could Help Change How Parkinson's Disease Is Treated

    The company's technology is helping researchers understand the genetic underpinnings of the disease.

    View More →
  • How 10x Genomics Is Turbocharging Genetic Research

    10x Genomics (NASDAQ: TXG) has achieved tremendous success over the last few years. Its technology is used by most of the top research laboratories across the world and by many leading biopharmaceutical companies. In this video recorded on March 11, 2021, Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics CEO and co-founder Serge Saxonov about how his company's platforms are turbocharging genomics research.

    View More →
  • How 10x Genomics Helped Achieve Breakthroughs in Cystic Fibrosis and COVID

    10x Genomics' (NASDAQ: TXG) technology has been used by researchers to investigate multiple diseases over the last few years. In this video recorded on March 11, 2021, Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Serge Saxonov about two areas where his company's technology has played especially important roles -- cystic fibrosis and COVID-19. Keith Speights: 10x's technology has been used in a lot of scientific discovery already.

    View More →
  • How Genomics Research Could Change How Multiple Sclerosis Is Treated

    Multiple sclerosis (MS) affects more than 1 million people in the U.S. But advances in treating the disease continue to be made, especially with new tools for genomic research into the underlying issues that lead to MS. In this video recorded on March 11, 2021, Jason Hall, multimedia specialist with The Motley Fool and the host of Discovery Now, talks with 10x Genomics (NASDAQ: TXG) CEO and co-founder Serge Saxonov about how genomics research could change how MS is treated. Jason Hall: One of our members, Paolo, has submitted a question and I want to put a twist on it.

    View More →
  • Could 10x Genomics Deliver a 10x Return?

    The company's CEO thinks it's capitalizing on the biggest value-creation opportunity of the next several decades.

    View More →
  • Butterfly, Trimble, 10X Genomics, Pluristem, Agora — What Cathy Wood's Ark Bought And Sold On Thursday

    Cathie Wood’s Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain stocks to see a spike in the after-hours session. Here’s a list of 7 stocks that the hedge fund bought and sold on Thursday. Trades For Ark Genomic Revolution ETF (NYSE: ARKG): Butterfly Network Inc (NYSE: BFLY): Bought 274,300 shares of the medical imaging devices company, representing about 0.049% of the ETF. Butterfly shares closed 3.33% lower at $16.27 on Thursday and were up 2.21% in the after-hours. It has a 52-week high of $29.13 and low of $9.34. 10X Genomics Inc (NASDAQ: TXG): Bought 79,573 shares of the gene sequencing biotechnology company, representing about 0.154% of the ETF. 10X shares closed 2.65% higher at $185.79 on Thursday. It has a 52-week high of $201.70 and low of $56.81. Phreesia Inc (NYSE: PHR): Sold 80,935 shares of the healthcare software services company, representing about 0.0465% of the ETF. Phreesia shares closed 5.82% higher at $55.13 on Thursday. It has a 52-week high of $81.59 and low of $17.27. Pluristem Therapeutics Inc (NASDAQ: PSTI): Sold 121,919 shares of the Israeli-based stemcell company, representing about 0.0063% of the ETF. Pluristem shares closed 0.84% higher at $4.81 on Thursday. It has a 52-week high of $13.29 and low of $3.09. Syros Pharmaceuticals Co (NASDAQ: SYRS): Sold 35,756 shares of the biopharmaceutical company that focuses on the development of treatments for cancer and monogenic diseases, representing about 0.003% of the ETF. Syros stock closed 1.27% lower at $7.38 on Thursday. It has a 52-week high of $15.65 and low of $5.14. Trades For Ark Innovation ETF (NYSE: ARKK): Trimble Inc (NASDAQ: TRMB): Bought 453,214 shares of the California-based hardware, software and services technology company, representing about 0.153% of the ETF. Trimble shares closed 3.79% higher at $80.74 on Thursday. Its has a 52-week high of $81.09 and low of $27.79. Trades For ARK Next Generation Internet ETF (NYSE: ARKW): Agora Inc (NASDAQ: API): Sold 104,001 shares of the software company, representing about 0.0789% of the ETF. Agora shares closed 6.86% higher at $53.72 on Thursday. It has a 52-week high of $114.96 and low of $33.60. See Also: Pinduoduo, Shopify, PayPal, LendingTree, JD.com — What Cathy Wood's Ark Bought And Sold On Wednesday See more from BenzingaClick here for options trades from BenzingaAnalyst Expects Tesla, GM To See EV Tax Credits Restored With Biden Kicking Off US 'Green Tidal Wave'Lordstown Motors Unveils Endurance Pickup Beta Versions© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • How Can Investors Find Innovative Companies Early?

    10x Genomics (NASDAQ: TXG) certainly stands out as an innovator in the genomics research world. In this video recorded on March 11, Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics CEO and co-founder Serge Saxonov about what factors to look for in identifying innovative companies. Tom Gardner: I'd love to hear from you what you see as some of the patterns of greatness in your category.

    View More →
  • 10x Genomics CEO: Why We're at the Beginning of a Biology Revolution

    Tom Gardner: We'd really love just the explanation to, let's say the 12-year-old in all of us that maybe hasn't yet gone on that biological journey. Maybe it was eighth grade was my first real biology class. Serge Saxonov: It's funny, as you mentioned, taking biology back in school because when I think back to when I took biology in high school, so much has advanced.

    View More →
  • What's Behind 10x Genomics' Acquisition Strategy?

    10x Genomics (NASDAQ: TXG) has gobbled up several smaller companies over the last year. These deals have extended the company's offerings and expanded its addressable market in some cases. In this video recorded on March 11, 2021, Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Serge Saxonov about his company's acquisition strategy.

    View More →
  • How Big Is 10x Genomics' Total Addressable Market?

    The genomics company's market cap now stands at close to $20 billion. In this video recorded on March 11, 2021, Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Serge Saxonov about just how big the company's total addressable market could be. Keith Speights: What is your total addressable market?

    View More →
  • Why 10x Genomics' CEO Is Optimistic About the Battle Against COVID

    Some areas of the U.S. and across the world are experiencing increased cases of COVID-19. However, there's also plenty of good news. In this video recorded on March 11, 2021, Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics (NASDAQ: TXG) CEO and co-founder Serge Saxonov about his perspective on the battle against COVID-19.

    View More →
  • How 10x Genomics Got Started

    10x Genomics (NASDAQ: TXG) has come a long way since opening its doors in 2012. The genomics company now has a market cap of close to $20 billion. In this video recorded on March 11, 2021, Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Serge Saxonov about how the pioneering company got started.

    View More →
  • 10x Genomics CEO Predicts What Healthcare Will Look Like 25 Years From Now

    In this video recorded on March 11, 2021, Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics (NASDAQ: TXG) CEO and co-founder Serge Saxonov about what he thinks healthcare will look like 25 years from now. Tom Gardner: You talked about what the world is going to look like 20-30 years from now and how different it is, healthcare. Serge Saxonov: Yeah, 25 years, and I think it's sufficiently long, where cancer -- as soon as there's anything that starts in your body -- starts growing in a way that it shouldn't, you would know about it very early, and you would have a huge arsenal of treatments that you can apply to fix that, to take care of that, to get rid of it right then and there.

    View More →
  • 10x Genomics Puts Single Cell Analysis Within Reach of All With Low Throughput Gene Expression Kit

    Along with recent release of CellPlex, product increases access through affordabilityPLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, a new offering designed to put the power of single cell analysis within the reach of more scientists than ever before. The new LT Kit reduces the startup cost for a single experiment, enabling a broader base of scientists to conduct single cell analysis. In addition, scientists now have the ability to use the 10x Genomics Cloud to perform a standard analysis of every sample at no additional cost, accelerating findings in a cost-effective manner. As a leader in single cell sequencing, 10x Genomics continues to develop products to accelerate access and affordability for a broader base of scientists across academia, research institutions, and pharmaceutical companies. Today’s news gives scientists a range of options to conduct single cell analysis from their first starter project of a few hundred cells to standard scale experiments of thousands to tens of thousands of cells all the way to high throughput million cell studies with the company’s next-generation Chromium X instrument, slated for release later this year. 10x Genomics recently started shipping its Single Cell Gene Expression with CellPlex, making single cell analysis on its standard kits more affordable. The CellPlex solution allows the multiplexing of up to 96 samples in a single chip, giving scientists the ability to drive larger experiments as they scale up from the LT Kit. CellPlex will also integrate into the company’s high throughput kits to be released with Chromium X. “Studying biology at the single cell level is at the core of any scientist's toolbox to make discoveries for the most pressing diseases and to advance human health,” said 10x Genomics Co-founder and Chief Scientific Officer Ben Hindson. “With the 10x Genomics Low Throughput Gene Expression Kit, we are democratizing single cell analysis, and we hope it catalyzes a whole new set of discoveries never imagined before.” “We are excited that the 10x Genomics Low Throughput kit will enable faster tech dev by allowing us to pilot and optimize experimental conditions,” said Joseph Replogle of the Whitehead Institute for Biomedical Research at MIT. “It will also broaden the biological applications we can explore, especially working in new cell and organoid models.” The Single Cell Gene Expression LT Kit offers several key features: Profiles gene expression for 100 to 1,000 single cells by barcoding mRNA at the 3’ end, allowing unbiased characterization of cell types and statesCombines gene expression analysis with detection of hundreds of cell surface proteins using oligonucleotide-conjugated antibodies for cellular phenotypingEnables cost-effective optimization of experimental conditions and sample prep to maximize the design and impact of single cell experiments Follows a ready-to-use, robust workflow with demonstrated protocols for diverse sample types, including cell lines, primary cells, and dissociated tissue The 10x Genomics Single Cell Gene Expression LT Kit is available now at https://pages.10xgenomics.com/lt-gene-expression-launch.html, and CellPlex at https://pages.10xgenomics.com/cellplex.html. About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world, including all of the top 100 global research institutions, as ranked by Nature in 2019, and all of the top 20 global pharmaceutical companies, as ranked by 2019 research and development spend, and have been cited in over 2,250 research papers on discoveries ranging from oncology to immunology, and neuroscience. The company’s patent portfolio comprises more than 1,000 patents and patent applications. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics product performance, configuration and capabilities and adoption. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19 pandemic. Other risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward- looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. ContactsMedia:media@10xgenomics.comInvestors:investors@10xgenomics.com

    View More →